While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price rose 0.1% on Tuesday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...

We recently published a list of Jim Cramer’s February Portfolio: Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Company (NYSE:LLY) stands against other stocks in ...

Six years ago, the average monthly out-of-pocket cost for insulin made by Eli Lilly ... them instead. Lilly, for example, recently revealed that the list price of its Humalog insulin held steady ...